How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

As organizations race to adopt artificial intelligence, the conversation has increasingly shifted from raw model performance to a more practical question: how can enterprises run AI at lower cost ...

Buffer overflow vulnerabilities have driven remote code execution for decades and keep appearing in critical network ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

OpenAI and Broadcom unveiled Jalapeño, a custom AI inference chip designed in nine months. Early tests show 50% cost savings over standard GPUs, with deployment planned for late 2026.

Ongoing research into AI agent framework security identified an exploit chain in AutoGen Studio (AutoGen’s open-source prototyping user interface) that allows untrusted web content rendered by a ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...

IBM just unveiled the world's first sub 1-nanometer chip: 100 billion transistors. IBM also says they've produced functioning ...

The company, along with others, is pursuing a new paradigm for cramming more transistors on chips—building up.

Un0 is an image-generation system tool that shows for the first time how the company's technology can replicate conventional ...

The ordinary graphite in pencil lead is proving to be surprisingly multifaceted at the microscale. In a study published in ...